Pulmonx（LUNG）株式概要
パルモンクス・コーポレーションは、慢性閉塞性肺疾患の一種である重度の肺気腫患者に低侵襲治療を提供する商業段階の医療技術企業である。 詳細
LUNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pulmonx Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.95 |
| 52週高値 | US$2.89 |
| 52週安値 | US$1.13 |
| ベータ | 0.34 |
| 1ヶ月の変化 | -12.56% |
| 3ヶ月変化 | 52.34% |
| 1年変化 | 25.81% |
| 3年間の変化 | -81.52% |
| 5年間の変化 | -94.94% |
| IPOからの変化 | -95.04% |
最新ニュース
Recent updates
分析記事 • Aug 01
Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40
Shareholders will be ecstatic, with their stake up 39% over the past week following Pulmonx Corporation 's...
ナラティブ更新 • Jul 09
LUNG: Index Reclassification And Improved Margins Will Support Future Upside
Analysts have adjusted their Pulmonx price target from $5.17 to $3.40, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Pulmonx Pulmonx was dropped from several Russell growth oriented benchmarks, including the Russell 3000 Growth, Russell 2000 Growth, Russell 2500 Growth, Russell 3000E Growth, Russell Small Cap Comp Growth, Russell 2000 Dynamic Index, and Russell Small Cap Completeness Index.
ナラティブ更新 • Jun 25
LUNG: 2026 Revenue Reaffirmation Will Support Confidence In Earnings Turnaround
Analysts have maintained their $5.00 price target on Pulmonx, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that, taken together, support keeping fair value at $5.00. What’s in the News for Pulmonx Pulmonx reaffirmed earnings guidance for fiscal 2026, indicating revenue expectations remain unchanged.ナラティブ更新 • Jun 07
LUNG: Reset Expectations And 2026 Guidance Will Underpin Turnaround Confidence
Analysts have reset their price target on Pulmonx from about $13.26 to $5.00 as they now apply lower revenue growth assumptions, slightly tighter discounting, and a modestly reduced future P/E multiple in their models. What's in the News Pulmonx reaffirmed earnings guidance for fiscal 2026 and said it continues to expect full-year revenue in the range of $90 million to $92 million.ナラティブ更新 • May 24
LUNG: Fundamentals Refocus And Internal Fixes Will Support Future Turnaround Confidence
Analysts recently cut their Pulmonx price target to $5 from $6, pointing to Q4 results that were largely in line with expectations while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more measured, but still constructive, stance toward Pulmonx.ナラティブ更新 • May 02
LUNG: Execution Improvements And Fundamentals Focus Will Support Future Turnaround Confidence
Analysts have trimmed their price target on Pulmonx to $5 from $6, reflecting Q4 results that were largely in line and management's efforts to address internal issues while refocusing on the fundamentals that previously supported the business. Analyst Commentary Bullish analysts are emphasizing that the trimmed US$5 price target still reflects confidence that Pulmonx can execute on its plan to resolve internal issues and refocus on the fundamentals that previously supported the business.ナラティブ更新 • Apr 18
LUNG: Fundamental Reset And Cleaner Execution Will Support Future Upside
Analysts have trimmed their Pulmonx price target to $5 from $6, citing largely in line Q4 results, management's explanation of last year's internal issues, and the company's renewed focus on the fundamentals that supported its earlier success. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$5 price target as reflecting a more grounded expectation for execution, with Q4 results described as largely in line rather than a negative surprise.ナラティブ更新 • Apr 04
LUNG: Cleaner Execution And Fundamentals Refocus Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to $5 from $6, pointing to Q4 results that were largely in line and to management's efforts to fix last year's internal issues while refocusing on the core fundamentals of the business. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q4 results being largely in line supports the current valuation reset, even with the lower US$5 price target.ナラティブ更新 • Mar 21
LUNG: Cleaner Execution And 2026 Revenue Guidance Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to about $5.17 from $5.75, reflecting updated views on revenue growth, profit margin expectations, and the impact of recent operational issues highlighted in Q4 commentary. Analyst Commentary Recent research suggests that the lower price target reflects a reset of expectations around execution while still acknowledging the core business case.ナラティブ更新 • Mar 06
LUNG: Operational Reset And Fundamentals Focus Will Support Turnaround Confidence
Analysts have lowered their price target on Pulmonx by $1 to $5, citing Q4 results that were broadly in line with expectations, while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more cautious, but still constructive, stance on Pulmonx.ナラティブ更新 • Feb 20
LUNG: Refined Risk And Margin Outlook Will Support Turnaround Confidence
Analysts have adjusted their Pulmonx price targets to reflect updated assumptions on discount rate, revenue growth, profit margin, and future P/E, keeping fair value around $13.49 while fine tuning the risk and earnings profile in their models. Valuation Changes Fair Value: Model fair value is unchanged at $13.49, indicating updated inputs did not shift the overall valuation level.分析記事 • Feb 11
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...ナラティブ更新 • Feb 06
LUNG: Firm Guidance And Margins Will Support Future Upside Potential
Analysts have kept their Pulmonx fair value estimate steady at US$5.75, with a slightly higher discount rate and P/E assumptions guiding the updated price target rationale. What's in the News Pulmonx issued new earnings guidance for full year 2025, setting an expected total revenue range of US$89 million to US$90 million.ナラティブ更新 • Jan 23
LUNG: Prior Leadership Return Will Drive Confidence In Turnaround Story
Narrative Update on Pulmonx Analysts have cut their price target on Pulmonx from $8 to $4, pointing to revised fair value assumptions and a lower future P/E multiple. At the same time, they highlight prior leadership returning and continued confidence in the Zephyr valves concept and the broader market opportunity.分析記事 • Jan 10
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...ナラティブ更新 • Jan 08
LUNG: Returning Leadership And Clinical Traction Will Support Future Upside Potential
Analysts have trimmed their price target on Pulmonx to US$4.00 from US$8.00, citing a reassessment of valuation, the return of prior leadership, and ongoing confidence in the clinical proof of concept for Zephyr valves and the broader market opportunity. Analyst Commentary Recent research commentary focuses on how the lower price target, leadership changes, and clinical track record of Zephyr valves fit together for investors weighing risk and potential reward.ナラティブ更新 • Dec 24
LUNG: Returning Leadership Will Drive Confidence Amid Near-Term Execution Uncertainty
Analysts have reduced their price target on Pulmonx to approximately $4.00 from $8.00, citing near term uncertainty around leadership changes but continued confidence in the long term opportunity, supported by Zephyr valve clinical validation and the broader product pipeline. Analyst Commentary Bullish Takeaways Bullish analysts highlight that even after the reduced price target, the implied upside still represents roughly a potential doubling from recent after hours trading levels, which underscores a favorable risk reward profile.ナラティブ更新 • Dec 10
LUNG: Returning Leadership Will Drive Confidence And Unlock Significant Upside Ahead
Analysts have reduced their price target on Pulmonx to about $4 from roughly $8, citing a lower discount rate along with confidence in returning leadership, robust clinical validation of Zephyr valves, and a solid market and pipeline opportunity that they still see as supporting substantial upside from current levels. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the lowered price target still implies meaningful upside from current trading levels, suggesting the market may be underestimating the company’s long term earnings potential.分析記事 • Dec 05
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has done very well over the last month, posting an excellent gain...ナラティブ更新 • Nov 26
LUNG: Returning Leadership Will Restore Confidence And Unlock Upside In Coming Year
Analysts have revised their price target for Pulmonx downward from $8 to $4 per share. They cite ongoing confidence in the company's clinical proof of concept and market opportunities, even in light of unexpected executive changes.ナラティブ更新 • Nov 12
LUNG: Leadership Transition Will Drive Renewed Execution Strength In The Coming Year
Analysts have revised Pulmonx’s price target downward from $8.00 to $4.00. They cite both leadership changes and ongoing belief in the company’s clinical achievements and long-term market potential as rationale for the adjustment.ナラティブ更新 • Oct 29
Leadership Return And Clinical Strength Will Drive Long-Term Market Opportunity
Analysts have lowered their price target for Pulmonx from $6.75 to $5.75, reflecting adjusted expectations on revenue growth and valuation. They remain optimistic, however, due to strong clinical evidence and a promising leadership transition.分析記事 • Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward
Those holding Pulmonx Corporation ( NASDAQ:LUNG ) shares would be relieved that the share price has rebounded 47% in...分析記事 • May 26
Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 40% in the last...分析記事 • Apr 11
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...
新しいナラティブ • Apr 01
LungTrax And Global Expansion Will Broaden Market Access
Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency.分析記事 • Feb 21
Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders of Pulmonx Corporation ( NASDAQ:LUNG ) will be pleased this week, given that the stock price is up 19% to...分析記事 • Feb 07
Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)
There wouldn't be many who think Pulmonx Corporation's ( NASDAQ:LUNG ) price-to-sales (or "P/S") ratio of 3.2x is worth...分析記事 • Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 26% in the last...Seeking Alpha • Jul 21
Pulmonx: Low Bar For Q2 Earnings
Summary New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses. Read the full article on Seeking Alpha分析記事 • Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...株主還元
| LUNG | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -1.5% | 0.7% | -1.1% |
| 1Y | 25.8% | -15.8% | 11.7% |
業界別リターン: LUNG過去 1 年間で-15.8 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: LUNG過去 1 年間で11.7 % の収益を上げたUS市場を上回りました。
価格変動
| LUNG volatility | |
|---|---|
| LUNG Average Weekly Movement | 15.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: LUNGの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: LUNGの weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1995 | 296 | Glen French | pulmonx.com |
パルモンクス・コーポレーションは、慢性閉塞性肺疾患の一種である重症肺気腫患者に低侵襲治療を提供する商業段階の医療技術企業である。Zephyr Endobronchial Valve、Chartis Pulmonary Assessment Systemを提供している。Chartis Pulmonary Assessment Systemは、側副換気の有無を評価するために使用される流量センサーと圧力センサーを備えたバルーンカテーテルとコンソールシステムである。また、クラウドベースの定量的コンピューター断層撮影分析サービスであるLungTraX Platformも提供しており、ワークアップの効率を向上させるLungTraX Connect、患者の特定を可能にするLungTraX Detect、ゼファーバルブによる治療の標的葉を特定するのに役立つ肺気腫破壊、亀裂の完全性、小葉容積に関する情報を含むソリューション用に設計されたStratX Lungレポートなど、複数の製品を医師に提供している。米国、欧州、中東、アフリカ、アジア太平洋地域、および国際的な肺気腫患者にサービスを提供している。同社は以前Pulmonxとして知られ、2013年12月にPulmonx Corporationに社名を変更した。Pulmonx Corporationは1995年に法人化され、カリフォルニア州レッドウッドシティに本社を置いている。
Pulmonx Corporation 基礎のまとめ
| LUNG 基礎統計学 | |
|---|---|
| 時価総額 | US$82.03m |
| 収益（TTM） | -US$48.12m |
| 売上高(TTM) | US$87.44m |
1.0x
P/Sレシオ-1.7x
PER（株価収益率LUNG は割高か？
公正価値と評価分析を参照収益と収入
| LUNG 損益計算書（TTM） | |
|---|---|
| 収益 | US$87.44m |
| 売上原価 | US$20.06m |
| 売上総利益 | US$67.38m |
| その他の費用 | US$115.50m |
| 収益 | -US$48.12m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.12 |
| グロス・マージン | 77.06% |
| 純利益率 | -55.03% |
| 有利子負債／自己資本比率 | 95.8% |
LUNG の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/16 09:17 |
| 終値 | 2026/09/16 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Pulmonx Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |